# Safety Study of LLF580 in Obese Volunteers

> **NCT03466203** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Obesity

## Interventions

- **BIOLOGICAL:** LLF580
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03466203
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466203, "Safety Study of LLF580 in Obese Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03466203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*